We are investigating the fairness of the proposed sale of Avid Bioservices (Nasdaq: CDMO) (“Avid”) to GHO Capital Partners (“GHO”) and Ampersand Capital Partners (“Ampersand”) for $12.50 per share in cash.
The sale price is below the price target for Avid of $14.00 per share of Wall Street analyst Paul Knight of KeyBanc (source: TipRanks).
If you remain an Avid shareholder and question the fairness of the price, you may contact our firm to discuss your legal rights at no charge by completing and submitting the form below.
Why is there an investigation?
On November 7, 2024, Avid announced that it had agreed to be sold to GHO and Ampersand for $12.50 per share in cash.
Notably, the sale price is below the price target for Avid of $14.00 per share of Wall Street analyst Paul Knight of KeyBanc (source: TipRanks).
“We are investigating whether the Avid Board of Directors acted in the best interests of Avid shareholders in approving the sale,” explained Joshua Fruchter, a founding partner of Wohl & Fruchter. “This includes whether the price agreed upon is fair to Avid shareholders, as well as whether all material information regarding the transaction has been fully disclosed.”